A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy

dc.authorid0000-0002-6839-2632
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorTaştekin, Didem
dc.contributor.authorKoca, Doğan
dc.contributor.authorGöksu, Sema Sezgin
dc.contributor.authorÜyetürk, Ümmügül
dc.contributor.authorKaplan, Mehmet Ali
dc.date.accessioned2021-06-23T19:53:47Z
dc.date.available2021-06-23T19:53:47Z
dc.date.issued2020
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: The most common age at which gastric cancer is diagnosed is 70 years, and the majority of patients diagnosed are at the metastatic stage. However, although gastric cancer is a geriatric disease, there is no suggestion to discriminate treatment for the general geriatric patient population. Here, we evaluated patients receiving palliative chemotherapy for gastric cancer owing to advanced age. Patients and Methods: Multicenter data of geriatric patients receiving palliative chemotherapy because of metastatic gastric cancer were retrospectively reviewed. Results: In total, 262 geriatric patients with gastric cancer were included in the study. Of these, 167 patients, including 134 (51.8%) patients with metastasis at diagnosis and 33 patients with relapse after surgery, were evaluated for palliative therapy. Chemotherapy was started in 87 (52.1%) of 167 patients. The overall median survival of the patients receiving chemotherapy was 9.3 months. There was no difference in overall survival (OS) between patients aged >70 and <70 years. However, a significant difference was detected in OS of patients depending on their Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment; survival was 15 months in the group with PS 0-1 and 7 months in the group with PS <greater than or equal to>2. Conclusion: Advanced age chemotherapy receiving rates in patients with metastatic gastric cancer is decreasing. Survival is not associated with age, but pretreatment ECOG PS is important. Therefore, ECOG PS and comorbidities should be evaluated in detail, and combination therapies could contribute to patient survival.en_US
dc.identifier.doi10.4103/jcrt.JCRT_563_18
dc.identifier.endpageS143en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.pmid33380668en_US
dc.identifier.scopus2-s2.0-85098942676en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageS138en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_563_18
dc.identifier.urihttps://hdl.handle.net/20.500.12491/10248
dc.identifier.volume16en_US
dc.identifier.wosWOS:000612861200024en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜyetürk, Ümmügül
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGeriatric Patientsen_US
dc.subjectMetastatic Gastric Canceren_US
dc.subjectSystemic Chemotherapyen_US
dc.titleA retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
ali-murat-tatli.pdf
Boyut:
731.94 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text